Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
ACS Synth Biol ; 12(4): 1331-1338, 2023 04 21.
Article in English | MEDLINE | ID: covidwho-2287537

ABSTRACT

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, exposed a pressing need for new public health tools for pathogen detection, disease diagnosis, and viral genotyping. REVEALR (RNA-encoded viral nucleic acid analyte reporter) is an isothermal DNAzyme-based point-of-care diagnostic that functions with a detection limit of ∼10 copies/µL when coupled with a preamplification step and can be utilized for viral genotyping of SARS-CoV-2 variants of concern through base pair mismatch recognition in a competitive binding format. Here, we describe an advanced REVEALR platform, termed digital droplet REVEALR (ddREVEALR), that can achieve direct viral detection and absolute sample quantitation utilizing a signal amplification strategy that relies on chemical modifications, DNAzyme multiplexing, and volume compression. Using an AI-assisted image-based readout, ddREVEALR was found to achieve 95% positive predictive agreement from a set of 20 nasal pharyngeal swabs collected at UCI Medical Center in Orange, California. We propose that the combination of amplification-free and protein-free analysis makes ddREVEALR a promising application for direct viral RNA detection of clinical samples.


Subject(s)
COVID-19 , DNA, Catalytic , Humans , COVID-19/diagnosis , SARS-CoV-2/genetics , Pandemics , RNA, Viral/genetics , Nucleic Acid Amplification Techniques , Sensitivity and Specificity
2.
Chemistry ; 29(27): e202300075, 2023 May 11.
Article in English | MEDLINE | ID: covidwho-2241149

ABSTRACT

A new method for the detection of genomic RNA combines RNA cleavage by the 10-23 DNAzyme and use of the cleavage fragments as primers to initiate rolling circle amplification (RCA). 230 different 10-23 DNAzyme variants were screened to identify those that target accessible RNA sites within the highly structured RNA transcripts of SARS-CoV-2. A total of 28 DNAzymes were identified with >20 % cleavage, 5 with >40 % cleavage and one with >60 % in 10 min. The cleavage fragments from these reactions were then screened for coupling to an RCA reaction, leading to the identification of several cleavage fragments that could efficiently initiate RCA. Using a newly developed quasi-exponential RCA method with a detection limit of 500 aM of RNA, 14 RT-PCR positive and 15 RT-PCR negative patient saliva samples were evaluated for SARS-CoV-2 genomic RNA, achieving a clinical sensitivity of 86 % and specificity of 100 % for detection of the virus in <2.5 h.


Subject(s)
Biosensing Techniques , COVID-19 , DNA, Catalytic , Humans , DNA, Catalytic/metabolism , RNA , SARS-CoV-2/genetics , SARS-CoV-2/metabolism , RNA Cleavage , COVID-19/diagnosis , Nucleic Acid Amplification Techniques/methods , Genomics , Biosensing Techniques/methods
3.
ChemMedChem ; 17(20): e202200382, 2022 10 19.
Article in English | MEDLINE | ID: covidwho-2013440

ABSTRACT

Nucleic acid-based detection of RNA viruses requires an annealing procedure to obtain RNA/probe or RNA/primer complexes for unwinding stable structures of folded viral RNA. In this study, we designed a protein-enzyme-free nano-construction, named four-armed DNA machine (4DNM), that requires neither an amplification stage nor a high-temperature annealing step for SARS-CoV-2 detection. It uses a binary deoxyribozyme (BiDz) sensor incorporated in a DNA nanostructure equipped with a total of four RNA-binding arms. Additional arms were found to improve the limit of detection at least 10-fold. The sensor distinguished SARS-CoV-2 from other respiratory viruses and correctly identified five positive and six negative clinical samples verified by quantitative polymerase chain reaction (RT-qPCR). The strategy reported here can be used for the detection of long natural RNA and can become a basis for a point-of-care or home diagnostic test.


Subject(s)
COVID-19 , DNA, Catalytic , Humans , SARS-CoV-2 , COVID-19/diagnosis , RNA, Viral/genetics , Real-Time Polymerase Chain Reaction
4.
Talanta ; 243: 123352, 2022 Jun 01.
Article in English | MEDLINE | ID: covidwho-1730116

ABSTRACT

Accurate identification of mutant pathogens derived from genetic polymorphisms is highly desired in clinical diagnosis. However, current detection methods based on Watson-Crick hybridization suffers from false positives due to the cross-reactivity of wild-type sequences. In this study, we developed an accurate identification of mutant pathogens by combining programmable DNAzyme and target nucleic acid sequence-triggered transcription. Single nucleotide variants (SNVs) are the most plentiful type of mutations in the genome. High specificity to discriminate SNV was first achieved by rational design of dual-hairpin DNA structure and DNAzyme's capability of site-specific cleavage. T7 RNA polymerase-mediated transcription amplification was introduced to exponentially increase the sensitivity by encompassing T7 promoter sequence into the dual-hairpin DNA structure. The design of this biosensor is fast and straightforward without many computational steps, and the highly sensitive biosensor can detect not only SNVs but also occasional insertions and large deletions in the genome. We showed that the assay could rapidly detect COVID-19 variant and methicillin-resistant Staphylococcus aureus (MRSA), and the limit of detection is 0.96 copy/µL. The modular design of functional DNA enables this biosensor be easily reconfigured and is useful diagnosis of emerging infectious diseases caused by mutant pathogens.


Subject(s)
Biosensing Techniques , DNA, Catalytic , Biosensing Techniques/methods , COVID-19/diagnosis , DNA, Catalytic/chemistry , DNA, Catalytic/genetics , Humans , Limit of Detection , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Nucleic Acid Amplification Techniques/methods , Nucleic Acid Hybridization , SARS-CoV-2/isolation & purification
5.
Sens Actuators B Chem ; 357: 131409, 2022 Apr 15.
Article in English | MEDLINE | ID: covidwho-1616767

ABSTRACT

Primer exchange reaction (PER) is an emergent method for non-templated synthesis of single stranded DNA molecules. PER has been shown to be effective in cell imaging systems and for detection of macromolecules. A particular application of PER is to detect a specific target nucleic acid. To this endeavor, two coupled DNA hairpins, a detector and an amplifier, play in accordance to extend a target nucleic acid with a concatemer DNA sequence. Here we introduced unified-amplifier based primer exchange reaction (UniAmPER) that beneficially extends the target by a unified-amplifier. The unified-amplifier operates as both detector and amplifier hairpins. The extension resulted in synthesis of concatemer G-rich sequences. The G-rich sequences were expected to form G-quadruplex (GQ) structures. Presence of the GQ structures were investigated by peroxidase activity of GQs in presence of hemin, H2°2 and 3,3',5,5'-Tetramethylbenzidine (TMB) as well as by fluorescence signal generation upon intercalation of thioflavin T (ThT). The presented unified-amplifier in this study facilitates application of PER systems for development of colorimetric or fluorogenic biosensors. As a proof of principle, the method has been applied for detection of reversely transcribed cDNAs from clinical SARS-CoV-2 samples.

6.
Biosens Bioelectron ; 201: 113944, 2022 Apr 01.
Article in English | MEDLINE | ID: covidwho-1588207

ABSTRACT

Coronavirus Disease 2019 (COVID-19), which poses an extremely serious global impact on human public healthcare, represents a high transmission and disease-causing viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that is expanding at a rapid pace. Therefore, it is urgent for researchers to establish effective platforms for the assay and treatment of SARS-CoV-2. Functional nucleic acids (FNAs), comprising aptamers and nucleases, are of primary concern within the biological and medical communities owing of the distinctive properties of their target recognition and catalysis. This review will concentrate on the essential aspects of insights regarding FNAs and their technological expertise for the diagnostic and therapeutic utilization against COVID-19. We first offer a historical perspective of the COVID-19 pandemics, its clinical characteristics and potential biomarkers. Then, we briefly discuss the current diagnostic and therapeutic methodology towards COVID-19, highlighting the superiorities and existing shortcomings. After that, we introduce the key features of FNAs, and summarize recent progress of in vitro selection of FNAs for SARS-CoV-2 specific proteins and RNAs, followed by highlighting the general concept of translating FNAs into functional probes for diagnostic and therapeutic purposes. Then, we critically review the emerging FNAs-based diagnostic and therapeutic strategies that are fast, precise, efficient, and highly specific to fight COVID-19. Finally, we identify remaining challenges and offer future outlook of this emerging field.


Subject(s)
Biosensing Techniques , COVID-19 , Nucleic Acids , Humans , Nucleic Acids/genetics , Pandemics , SARS-CoV-2
7.
Biosens Bioelectron ; 187: 113280, 2021 Sep 01.
Article in English | MEDLINE | ID: covidwho-1213052

ABSTRACT

In order to define public health policies, simple, inexpensive and robust detection methods for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are vital for mass-testing in resource limited settings. The current choice of molecular methods for identification of SARS-CoV-2 infection includes nucleic acid-based testing (NAT) for viral genetic material and antigen-based testing for viral protein identification. Host exposure is detected using antibody detection assays. While NATs require sophisticated instrument and trained manpower, antigen tests are plagued by their low sensitivity and specificity. Thus, a test offering sensitive detection for presence of infection as a colorimetric readout holds promise to enable mass testing in resource constrained environments by minimally trained personnel. Here we present a novel HRPZyme Assisted Recognition of Infection by Optical Measurement (HARIOM) assay which combines specificity of NATs with sensitivity of enzymatic assays resulting in enhanced signal to noise ratios in an easily interpretable colorimetric readout. Using this assay, we could detect up to 102 copies of synthetic viral RNA spiked in saliva as a detection matrix. Validating our assay on suspected human subjects, we found concordance with PCR based readouts with visible colorimetric distinction between positive and negative samples in less than an hour. We believe that this assay holds the potential to aid in mass screening to detect SARS-CoV-2 infection by facilitating colorimetric detection with minimal resources and less trained personnel.


Subject(s)
Biosensing Techniques , COVID-19 , Humans , Nucleic Acid Amplification Techniques , RNA, Viral , SARS-CoV-2 , Saliva , Sensitivity and Specificity
8.
Front Mol Biosci ; 7: 586254, 2020.
Article in English | MEDLINE | ID: covidwho-1021900

ABSTRACT

The gold standard for the diagnosis of SARS-CoV-2, the causative agent of COVID-19, is real-time polymerase chain reaction (PCR), which is labor-intensive, expensive, and not widely available in resource-poor settings. Therefore, it is imperative to develop novel, accurate, affordable, and easily accessible assays/sensors to diagnose and isolate COVID-19 cases. To address this unmet need, we utilized the catalytic potential of peroxidase-like DNAzyme and developed a simple visual detection assay for SARS-CoV-2 RNA using a conventional thermal cycler by the PCR-induced generation of DNAzyme sensor. The performance of RT-PCR DNAzyme-based sensor was comparable to that of real-time PCR. The pilot scale validation of RT-PCR DNAzyme-based sensor has shown ~100% sensitivity and specificity in clinical specimens (nasopharyngeal swab, n = 34), with a good correlation (Spearman r = 0.799) with the Ct-value of fluorescence probe-based real-time PCR. These findings clearly indicate the potential of this inexpensive, sensitive, and specific molecular diagnostic test to extend our testing capabilities for the detection of SARS-CoV-2 to curtail COVID-19 transmission.

SELECTION OF CITATIONS
SEARCH DETAIL